Thanks to you Dave for the video link.Despite having watched all...

Thanks to you Dave for the video link.

Despite having watched all of LC's and YF previous presentations this one is the most educating one. Especially at the end, when he talks about combinations with check point inhibitor drugs and CD 19 - CAR-Ts (and IMU's allogeneic Azer-Cel) the current trial designs and the enormous progress signed off by the FDA make a lot of sense.

But, the Q & A section showed how less actually is known about CF 33 outside the FDA and the small group that is involved with the trials.

Maybe that's one reason why IMU hasn't attracted any big pharma and real LT investor - still unknown.

I have sent the webinar coordinator, Prof Stephanie Roessler, a link to IMU's website and to the Uni Vienna's one as well as there was a reference to HER 1,2,3. Seemed like she and the other participants heard about the CF 33 virus for the first time. If she can spread the word - can't hurt.

So much progress on the clinical front and yet, IMU, RAD despite a cracker anns today got shot down and CHM still suspended and no explanation given by management.

The gap widens almost on a daily basis but the video proves, the clinical front can't be blamed for that.

GLTA